Optimizing endovascular thrombectomy timing and thrombolysis use for ischemic stroke: insights from the SELECT2 and TIMELESS trials
Gauthier Nendumba,Julien Moury,Michael Van Nieuwenhove,Arnaud Robert,Benedicte Hauqiert,Ovidiu Vornicu,Sydney Blackman,Emily Perriens,Ryma Ghorayeb,Sofia Belhoussine Drissi,Patrick El Nawar,Alexis Philippot,Anne-Sophie Dincq,Patrick Evrard,Pierre Bulpa,Isabelle Michaux,Patrick M. Honore
DOI: https://doi.org/10.21037/atm-24-64
IF: 3.616
2024-10-19
Annals of Translational Medicine
Abstract:Gauthier Nendumba 1 , Julien Moury 1 , Michael Van Nieuwenhove 1 , Arnaud Robert 1 , Benedicte Hauqiert 1 , Ovidiu Vornicu 1,2 , Sydney Blackman 3 , Emily Perriens 4 , Ryma Ghorayeb 4 , Sofia Belhoussine Drissi 4 , Patrick El Nawar 4 , Alexis Philippot 4 , Anne-Sophie Dincq 1,2 , Patrick Evrard 1 , Pierre Bulpa 1 , Isabelle Michaux 1 , Patrick M. Honore 1 1 ICU, CHU UCL Godinne Namur, UCL Louvain Medical School, Yvoir, Belgium; 2 ICU and Anesthesiology Departments, CHU UCL Godinne Namur, UCL Louvain Medical School, Yvoir, Belgium; 3 ULB University Centre Hospitalier Universitaire Brugmann, Brussels, Belgium; 4 ULB University, Brussels, Belgium Comment on: Sarraj A, Abraham MG, Hassan AE, et al . Endovascular thrombectomy plus medical care versus medical care alone for large ischaemic stroke: 1-year outcomes of the SELECT2 trial. Lancet 2024;403:731-40. Keywords: Thrombectomy; thrombolysis; stroke; ischemic stroke Submitted Mar 29, 2024. Accepted for publication Aug 21, 2024. Published online Aug 30, 2024. doi: 10.21037/atm-24-64 The SELECT2 trial was designed to assess the long-term functional status of patients with large ischemic strokes at 1-year post-endovascular thrombectomy, as opposed to the established 3-month period during which improved functional status has already been established (1). Nine years ago, randomized controlled studies demonstrated the superiority of endobacterial thrombectomy over classical treatment in patients with cerebral vascular accident induced by vascular thrombosis in the bilateral internal carotid arteries (ICAs) and supplies blood to the majority of the cerebral hemispheres, including the frontal lobes, parietal lobes, lateral temporal lobes and anterior part of deep cerebral hemispheres. Nevertheless, the authors expressed concerns about the clinical outcomes of patients with large-core strokes following reperfusion. They observed that the number of sick persons achieving self-reliance and the ability to walk freely in those studies was significantly reduced compared to early studies of removal of a blood clot for sick persons with favorable scanners and limited ischemic modifications (2). Therefore, for large ischemic strokes, there was uncertainty about whether endovascular thrombectomy yielded superior long-term functional outcomes compared to thrombolysis alone (3,4). The TIMELESS study addresses another area of medical uncertainty. Its aim was to with thrombolysis improve better recovery in sick patients with cerebral vascular accidents due to blood clots who were admitted later than 4.5 hours but within 24 hours after symptom onset. In these patients, thrombectomy is utilized if indicated. Patients eligible for inclusion were those within 24 hours of ischemic stroke onset and last known to be well. They were randomly assigned to thrombectomy (178 patients), with 21% receiving thrombolysis, or to medical care only (174 patients), with functional outcome as the primary endpoint (5). Clot mechanical removal ameliorates with the significance of a specific scoring system after 12 months (modified ranking scale) compared to controls. A specific statistical analysis did show an important neurological gain with a P value of 0.0019. After 12 months 45% with clot mechanical removal passed away and 52% in the control group. This was not significant (1). These findings are reassuring as they confirm the results of another recent trial published by Sarraj et al. , which compared thrombectomy with medical treatment to medical treatment alone for large ischemic strokes (6). Indeed, in Sarraj study after 3 months using the same specific statistical analysis did show an important neurological gain as well with a P value of 0.001. In the TIMELESS trial, Albers et al. (7) conducted a comparative analysis of tenecteplase versus placebo, both administered with thrombectomy if indicated. This treatment was given within 4 to 24 hours after the sick person was still in good neurological shape among individuals exhibiting indications of salvageable tissue on perfusion imaging. In this study, the data obtained using the same specific statistical analysis did not show an important neurological gain for thrombolysis versus control arm. In summary, tenecteplase therapy started at four and a half up to 24 hours after cerebral vascular accident was not associated with a neurological improvement as compared to placebo. Conversely, within the SELECT2 trial, 21% of the thrombectomy cohort also received thrombolysis. However, the specific timing of thrombolytic administration remains ambiguous, described as occurring within 24 hours of stroke onset wi -Abstract Truncated-
oncology,medicine, research & experimental